Cartography Biosciences and Pfizer Forge ~$865M Deal for Discovery of Tumor-Selective Antigens

Shots: Cartography has entered into a strategic collaboration with Pfizer to discover tumor-selective antigens, leveraging Cartography’s ATLAS & SUMMIT platforms Under a multi-year deal, Cartography will discover & validate tumor-selective antigens in an undisclosed cancer, with Pfizer holding opt-in rights for research, development & commercialization; Cartography retains full ownership of its lead asset CBI-1214 Cartography…

ByRidhi RastogiJanuary 7, 2026

NEWS

Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for NonAdvanced Systemic Mastocytosis

Shots: The US FDA has received the NDA of bezuclastinib for the treatment of NonAdvanced Systemic Mastocytosis (NonAdvSM) NDA was supported by the SUMMIT trial, which met its 1 & 2EPs, showing clinical benefit across all symptom domains, incl. 11 individual patient-reported symptoms as well as the most severe symptom, along with correlated biomarker reductions…

ByRidhi RastogiDecember 31, 2025

NEWS

Cogent Biosciences Reports P-III (PEAK) Trial Data on Bezuclastinib Combination for Gastrointestinal Stromal Tumors (GIST)

Shots: Cogent Biosciences has reported the P-III (PEAK) trial data assessing bezuclastinib + sunitinib vs sunitinib monotx. in pts with imatinib-resistant or intolerant GIST; the US FDA’s NDA filing is planned for H1’26 As of Sep 30, 2025, trial met its 1EP of improved PFS (mPFS: 16.5 vs 9.2mos.) & showed ORR of 46% vs…

ByRidhi RastogiNovember 11, 2025

EVENTS

Global PHT Expo & Summit 2023, An International Conference & Exhibition on Pharma, Healthcare & Technology

Weece Events is glad to invite you to attend the Global PHT Expo & Summit 2023 which is an International Conference & Exhibition on PHARMA, HEALTHCARE & TECHNOLOGY focusing on the Future of the Global Pharma & Healthcare Ecosystem in a digitally transforming world. The event is happening from 15-17th Feb 2023 at Hyatt Centric,…

BySenior EditorJanuary 25, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

Cartography Biosciences and Pfizer Forge ~$865M Deal for Discovery of Tumor-Selective Antigens

Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for NonAdvanced Systemic Mastocytosis

Cogent Biosciences Reports P-III (PEAK) Trial Data on Bezuclastinib Combination for Gastrointestinal Stromal Tumors (GIST)

Global PHT Expo & Summit 2023, An International Conference & Exhibition on Pharma, Healthcare & Technology

PharmaShots’ Key Highlights of Fourth Quarter 2022

Contact US

FOLLOW US